Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,25459938,Cmax,The study indicated that 9.5% of free form of fidarestat may be pharmacologically active and the Cmax for free fidarestat was found to be 80.30 ± 6.78 ng/mL.,"Plasma protein binding, pharmacokinetics, tissue distribution and CYP450 biotransformation studies of fidarestat by ultra high performance liquid chromatography-high resolution mass spectrometry. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25459938/),[ng] / [ml],80.30,223350,DB02021,Fidarestat
,25459938,AUC0-t,"The AUC0-t and AUC0-∞ were found to be 185.46 ± 32 and 195.92 ± 15.06 ng h/mL, respectively.","Plasma protein binding, pharmacokinetics, tissue distribution and CYP450 biotransformation studies of fidarestat by ultra high performance liquid chromatography-high resolution mass spectrometry. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25459938/),[h·ng] / [ml],185.46,223351,DB02021,Fidarestat
,25459938,AUC0-∞,"The AUC0-t and AUC0-∞ were found to be 185.46 ± 32 and 195.92 ± 15.06 ng h/mL, respectively.","Plasma protein binding, pharmacokinetics, tissue distribution and CYP450 biotransformation studies of fidarestat by ultra high performance liquid chromatography-high resolution mass spectrometry. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25459938/),[h·ng] / [ml],195.92,223352,DB02021,Fidarestat
